TURNING POINT THERAPEUTICS I (TPTX) Stock News
NASDAQ:TPTX - Nasdaq - US90041T1088 - Common Stock - Currency: USD
TPTX Latest News, Press Relases and Analysis
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of...
Turning Point Secures Positive FDA Feedback For Planned Lung Cancer Drug Submission
Turning Point Therapeutics (NASDAQ: TPTX) has received positive feedback from the U.S. Food and Drug Administration (FDA) at a pre-New Drug Application (NDA) meeting completed in the second quarter.
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
Completed pre-NDA meeting to discuss proposed patient follow-up in ROS1+ advanced NSCLC with FDA...
The 3 Best Market Sectors for the Second Half of 2022
Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.
Turning Point Therapeutics shares more than doubled on Friday
Bristol-Myers says it will buy Turning Point Therapeutics for $4.10 billion. Turning Point Therapeutics shares jumped over 100% on Friday.
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
Shockwave and UnitedHealth lead 5 stocks that are setting up or breaking out.
Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies
HOUSTON and SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company...
INVESTIGATION ALERT: Halper Sadeh LLP Investigates VMW, TPTX, CTT, CTEK
NEW YORK, NY / ACCESSWIRE / June 9, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
SHAREHOLDER ALERT: Weiss Law Investigates Turning Point Therapeutics, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Turning Point...
Mentions: BMY
